A task force of the American Society for Bone and Mineral Research (ASBMR) has released new recommendations delineating the potential benefits and risks of prolonged therapy with oral and IV bisphosphonate therapy and providing guidance on duration of bisphosphonate therapy for postmenopausal osteoporosis.1 The task force makes clear that data and clinical experience on which…
Associate Editor of The Rheumatologist on Working Sabbatical Maura Daly Iversen, PT, DPT, SD, MPH, professor and chair of the Department of Physical Therapy, Movement, and Rehabilitation Sciences at Northeastern University, a behavioral scientist in the Division of Rheumatology, Immunology, and Allergy at Brigham and Women’s Hospital, a lecturer at Harvard Medical School, Boston, and…
“No more excuses.” At least, that’s what Amanda Nelson, MD, MSCR, now tells her patients. As a rheumatologist, assistant professor in the School of Medicine at the University of North Carolina at Chapel Hill (UNC) and clinical researcher at UNC’s onsite Thurston Arthritis Research Center, Dr. Nelson says patients often provide a litany of legitimate—and sometimes…
Dear Friends and Colleagues, With your strong support and commitment, RheumPAC has grown again for the eighth straight year, allowing us to do even more on your behalf. Not only did we exceed our original goal by raising more than $150,000. More importantly, these donations came from nearly 350 ACR and ARHP members—a new record….
Adapting to new standards of training for physicians has been difficult across specialties. But Calvin Brown Jr., MD, says that by investing time and patience to understand the big picture, rheumatologists will benefit from the Accreditation Council for Graduate Medical Education’s Next Accreditation System…
(Reuters)—The U.S. Attorney’s Office for the Southern District of New York is investigating contracts between drugmakers and companies that manage prescription benefits, according to regulatory filings. Federal prosecutors have approached at least three companies, including Johnson & Johnson, Merck & Co. and Endo International Plc., demanding information about their contracts with pharmacy benefit managers. Pharmacy…
A recent study found that plasmacytoid dentricitic cells (pDCs) control the differentiation of immature B cells into regulatory B (Breg) cells or plasmablast, depending on the concentration of IFNα. For patients with SLE, researchers found that immune regulatory feedback between pDCs and Breg cells is dysfunctional, with the exception of patients who respond to rituximab…
Two studies have shown that romosozumab is effective for increasing bone mineral density in both men and women with osteoporosis. And due to safety concerns, Janssen has dropped out of clinical trials for fulranumab, which is being studied to treat OA pain…
NEW YORK (Reuters Health)—The investigational drug abaloparatide may help postmenopausal women increase their bone mineral density (BMD) and reduce their risk of fracture, new industry research suggests. “What was surprising and very important about this study was that, although some drugs for osteoporosis don’t work across all patient subgroups, abaloparatide provided persistent protection against fracture…
Researchers suspect the C-type lectin receptor (CLR) mincle may play a role in experimental autoimmune uveoretinitis. A new study linked CLR mincle to Card9-signaling events and IL-1, resulting in inflammation…